Research on the Brain Glymphatic System of Parkinson's Disease Patients Based on DTI Technology

Launched by THE FIRST PEOPLE'S HOSPITAL OF YUNNAN · Feb 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the brain's glymphatic system—responsible for removing waste from the brain—functions in patients with Parkinson's disease (PD). Researchers will use a special imaging technique called DTI-ALPS, which is non-invasive, to assess changes in this system at different stages of the disease. The goal is to see if this imaging method can help diagnose Parkinson’s disease early and track its progression over time.

To participate in this study, candidates must be diagnosed with primary Parkinson's disease and be able to undergo a brain MRI scan. Eligible participants will be grouped based on how advanced their Parkinson's disease is, and they will be compared to healthy volunteers. Throughout the study, participants can expect to undergo MRI scans and provide some clinical information, which will help researchers understand the relationship between brain function and Parkinson's symptoms. This research could lead to better tools for diagnosing and monitoring Parkinson's disease in the future.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria:(1) All the selected candidates were diagnosed in accordance with the "Diagnostic Criteria for Parkinson's Disease in China" (2016 edition) formulated by the International Society of Parkinson's Disease and Movement Disorders and the Parkinson's Disease and Movement Disorders Group and Special Committee of China; (2) Able to cooperate with and tolerate cranial magnetic resonance examination; (3) All are effective against dopamine drugs.
• • - Exclusion Criteria:(1) secondary parkinsonism (such as after encephalitis, long-term use of neuroleptics such as phenothiazines and butyryls and other drugs such as reserpine, history of toxic exposure, history of vascular diseases such as cerebral infarction or hemorrhage in the basal ganglia, history of traumatic brain injury, abnormal thyroid function, etc.); (2) Parkinson's superposition syndrome (such as progressive supranuclear palsy, olivine pontine cerebellar atrophy, corticobasal ganglia degeneration, Lewy body dementia, Shv. Dräger syndrome, etc.); (3) hereditary degenerative parkinsonism; (4) Patients with diabetes mellitus and end-stage renal disease; (5) Those with contraindications to magnetic resonance examination.
• • -